Microbion Corporation
✓ Verified ManufacturerAbout
Microbion Corporation is a clinical-stage pharmaceutical manufacturing company headquartered in Bozeman, Montana, specializing in the development of innovative anti-infective therapeutic compounds. Founded in 2000, the company focuses on creating novel treatments for difficult-to-treat and antibiotic-resistant infections, addressing critical healthcare challenges in the pharmaceutical industry. The company's flagship product, pravibismane, represents a breakthrough first-in-class therapeutic with unique anti-infective, antibiofilm, and anti-inflammatory properties. This innovative compound utilizes a site-specific delivery approach that enables higher therapeutic concentrations at infection sites, resulting in enhanced efficacy and improved safety profiles. Pravibismane has earned prestigious FDA designations including Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug status. Microbion Corporation currently operates multiple clinical development programs, including two Phase 2 studies for diabetic foot ulcers and orthopedic device infections, with Phase 3 trials planned for 2025. The company also maintains a pre-clinical respiratory infection program, demonstrating its commitment to addressing diverse medical needs. With over 22 million dollars in grant funding from the U.S. Department of Defense, NIH, CARB-X, and the Cystic Fibrosis Foundation, Microbion Corporation continues advancing pharmaceutical manufacturing innovation from its Montana facility, contributing to the fight against antimicrobial resistance.